Navigation Links
Montreal researchers shed light on common juvenile cancer
Date:6/16/2010

This release is available in French.

Montreal, June 16, 2010 A team of researchers from the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.

The study was conducted by primary authors Mathieu Tremblay, Ph.D. student and Cdric Tremblay, post-doctoral fellow in the Hematopoiesis and Leukemia Laboratory at the Universit de Montral and led by corresponding author and IRIC Principal Investigator, Trang Hoang.

Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancers and affects lymphocytes, the cells in the body that normally fight infections. ALL starts when a single, immature white blood cell called a "blast" develops a series of mistakes or mutations that allow it to multiply uncontrollably. Eventually, these leukemic blasts take over the lymphoid organs, the bone marrow and crowd out normal blood cells.

While extensive research has been conducted over the years to understand this type of cancer, deciphering the complex process responsible for transforming normal cells into cancerous cells remains a challenge. In this study, researchers started from the well-known basis that the interaction between two genes, SCL and LMO, is involved at the onset of a specific type of ALL, called T-cell leukemia.

"We wanted to uncover the precise mechanism behind the process that causes a normal cell to become cancerous. Our study reveals that SCL and LMO expand the pool of immature lymphocytes, which proliferate intensively under the influence of a specific signal. These SCL-LMO-primed cells then acquire mutations in a third gene, Notch1, which is known to play a role in the majority of T-ALL patients," explains Trang Hoang. "In short, the synergy between these three genes in a permissive cell is sufficient to induce leukemia."

Although chemotherapy can cure up to 80 percent of ALL in children, researchers hope to minimize the side effects by designing new therapies that specifically target cancer causing genes. "The knowledge from our study could be instrumental in the development of less invasive cancer therapies," adds Dr. Hoang.


'/>"/>

Contact: Carolyne Lord
carolyne.lord@umontreal.ca
514-343-7282
University of Montreal
Source:Eurekalert

Related medicine news :

1. UCSF Researchers Identify Regulator of Human Sperm Cells
2. Researchers find broad spectrum antiviral that fights multitude of viruses
3. University of Alberta researchers develop drug interface to save lives
4. Caregivers of ICU patients are collateral damage of critical illness, say Pitt researchers
5. Researchers fight world hunger by mapping the soybean genome
6. HIV researchers solve key puzzle after 20 years of trying
7. UC Davis researchers identify brain protein for synapse development
8. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
9. Researchers find new way to study how enzymes repair DNA damage
10. UCLA researchers image earliest signs of Alzheimers, before symptoms appear
11. Researchers find leukemia cells metabolize fat to avoid cell death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology: